Progress report from the NIDA Addiction Research Center (preclinical laboratory), Lexington, Kentucky.
D000818:Animals; D014151:Anti-Anxiety Agents / Q000037:antagonists & inhibitors; D001569:Benzodiazepines; D003042:Cocaine / Q000494:pharmacology; D004285:Dogs; D006168:Guinea Pigs; D006801:Humans; D007700:Kinetics; D008297:Male; D009538:Nicotine / Q000494:pharmacology; D009293:Opioid-Related Disorders / Q000378:metabolism / Q000503:physiopathology*; D010111:Oxymorphone / Q000378:metabolism; D010620:Phenazocine / Q000031:analogs & derivatives / Q000494:pharmacology; D010622:Phencyclidine / Q000494:pharmacology; D051381:Rats; D012646:Self Administration; D013237:Stereoisomerism
D014151:Anti-Anxiety Agents; D001569:Benzodiazepines; D009538:Nicotine; C012134:SK&F 10047; D010111:Oxymorphone; D003042:Cocaine; D010620:Phenazocine; D010622:Phencyclidine